XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024
20 8월 2024 - 8:00PM
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ:
XRTX | TSXV: XRTX | Frankfurt: ANUA), a late-stage
clinical pharmaceutical company focused on developing innovative
therapies to treat progressive kidney disease, is pleased to
announce the acceptance of an abstract submitted to the American
Society of Nephrology (the “ASN”). The abstract entitled
"Xanthine oxidase in rats, mice and humans with polycystic
kidney disease" was reviewed by the ASN review panel for
scientific merit and novel discoveries. The study was
conducted at the University of Colorado in the independent
laboratory of Dr. Charles Edelstein and was sponsored by XORTX and
will be presented during the Session Title: Genetic Diseases:
Cystic - Therapeutic Investigations and Prognosis.
About this study
The xanthine oxidase (“XO”) enzyme is an
essential enzyme within the uric acid pathway, and is required for
the breakdown of purine nucleotides. Uric acid as well as reactive
oxygen species released during the enzymatic reaction may also
play a detrimental role in the circulatory system and within tissue
during disease. Recent pioneering discoveries in rodent models of
polycystic kidney disease (“PKD”) implicate over expression or over
activity of XO. It is currently unknown if XO over expression or
over activity in humans is associated with PKD or more rapid
progression of disease. The aim of the study was to
gain insight into whether increased XO activity results in cyst
growth, XO activity was measured in PCK1 rats, PKD1RC/RC (RC) mice
and 34 patients from the HALT-PKD Clinical study.
The abstract outlines study results from mouse,
rat and human studies of PKD. The purpose of the study was to gain
an understanding of serum xanthine oxidase activity (XOa) in PKD
during varied stages of disease and further to relate that activity
to total kidney volume, and decline of glomerular filtration rate
(GFR). The results of the study provide understanding of
where aberrant purine metabolism in PKD tissue due to sources XO
enzyme may contribute to circulating uric acid levels, expansion
rate of kidney and cyst and functional GFR decline. Prior
study results suggested over expression of XO in PKD kidney tissue
may be a feature of cystic disease. XORTX will provide a further
update on the results of the study during the first week of
November.
Dr. Allen Davidoff, CEO of XORTX, stated, “We
are pleased to once again be presenting pioneering studies in PKD
due to ADPKD at the American Society of Nephrology annual meeting
during Kidney Week 2024 with this poster presentation. Most
importantly, results of this study deepen our understanding of how
increased serum uric acid or aberrant kidney tissue expression of
XO contribute to accelerate injury using data from mouse, rat and
human studies of PKD. The XRx-008 program continues to pioneer our
understanding of how too much or too active xanthine oxidase may
result in a health consequence in PKD.”
About the American Society of Nephrology
– Kidney Week
ASN represents more than 21,000 kidney health
professionals working to help people with kidney diseases and their
families. (Source: https://www.asn-online.org/)
The Kidney Week Conference is attended by
approximately 10,000 other kidney professionals from across the
globe at Kidney Week 2024 in Orlando, Florida. The world's premier
nephrology meeting, Kidney Week provides participants with exciting
and challenging opportunities to exchange knowledge, learn the
latest scientific and medical advances, and listen to engaging and
provocative discussions with leading experts in the field. (Source:
https://www.asn-online.org/education/kidneyweek/American Society of
Nephrology - Program and Abstracts)
The Kidney Week program is available on the ASN
website. Abstracts will be available on the ASN website by October
14, 2024.
About ADPKD
ADPKD is a rare disease that affects more that
10 million individuals worldwide.1,2 ADPKD is typically diagnosed
based upon expansion of fluid-filled cysts in the kidneys. Over
time, the increasing number and size of cysts can contribute to
structural and functional changes to kidneys and is frequently
accompanied by chronic pain which is a common problem for patients
with ADPKD.3 Expansion of cysts is thought to compress healthy
functioning tissue surrounding the cysts and contribute to further
loss of kidney function, fibrosis, impaired nutrient exchange and
impaired kidney function, accompanied later by end-stage renal
disease.1 Health consequences of high uric acid have been reported
to be increased in ADPKD individuals, including increased incidence
of kidney stones5 and gout.6,7 For individuals with progressing
ADPKD, treatment recommendations include anti-hypertensive
treatment, dietary restrictions, and, for a limited percentage of
suitable patients, pharmacotherapy.4 New, more broadly applicable
therapies to effectively slow decline of kidney function in ADPKD
are needed.
References:
- Wiley C., Kamat S., Stelhorn R.,
Blais J., Analysis of nationwide date to determine the incidence
and diagnosis of autosomal dominant polycystic kidney disease in
the USA, Kidney Disease, 5(2): 107-117, 2019
- Bergmann C., Guay-Woodford L.M.,
Harris P.C., Horie S., Peters D.J., Torres V.E., Polycystic Kidney
Disease, Nat Rev Dis Primers. 4(1): 50, 2018
-
https://pkdcure.org/living-with-pkd/chronic-pain-management
- Gimpel C., Bergmann C., Bockenhauer
D., et al., International consensus statement of the diagnosis and
management of autosomal dominant polycystic kidney disease in
children and young people, Nat Rev Nephrol 15(11):713-726,
2019
- Torres VE, et al, The association
of nephrolithiasis and autosomal dominant polycystic kidney
disease, Am J Kidney Dis, 1988, vol 11, 318-325
- Newcombe, DS. Letter Gouty
Arthritis and polycystic kidney disease, Ann Intern Med, 1973 vol
79, pg 605
- Rivera JV Martinez, et al,
Association of hyperuricemia and polycystic kidney disease, Bol
Asoc Med P R, 1965 vol 7 251-263
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development: 1) our lead, XRx-008
program for ADPKD; and 2) our secondary program in XRx-101 for
acute kidney and other acute organ injury associated with
Coronavirus / COVID-19 infection. In addition, XRx-225 is a
pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX
is working to advance its clinical development stage products that
target aberrant purine metabolism and xanthine oxidase to decrease
or inhibit production of uric acid. At XORTX, we are dedicated to
developing medications to improve the quality of life and future
health of patients. Additional information on XORTX is available at
www.xortx.com.
For more
information, please contact: |
|
|
|
Allen Davidoff, CEO |
Nick Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403 455 7727 |
nick@alpineequityadv.com or +1 617 901 0785 |
|
|
Kim Golodetz, LHA Investor Relations |
|
kgolodetz@lhai.com or +1 212 838 3777 |
|
|
|
Neither the TSX Venture Exchange nor Nasdaq has approved or
disapproved the contents of this news release. No stock exchange,
securities commission or other regulatory authority has approved or
disapproved the information contained herein.
Forward Looking
Statements
This press release contains express or implied
forward-looking statements pursuant to applicable securities laws.
These forward-looking statements include, but are not limited to,
the Company's beliefs, plans, goals, objectives, expectations,
assumptions, estimates, intentions, future performance, other
statements that are not historical facts and statements identified
by words such as "expects", "anticipates", "intends", "plans",
"believes", "seeks", "estimates" or words of similar meaning.
These forward-looking statements and their implications are
based on the current expectations of the management of XORTX only,
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. Such risks, uncertainties, and
other factors include, but are not limited to, our ability to
obtain additional financing; the accuracy of our estimates
regarding expenses, future revenues and capital requirements; the
success and timing of our preclinical studies and clinical trials;
the performance of third-party manufacturers and contract research
organizations; our plans to develop and commercialize our product
candidates; our plans to advance research in other kidney disease
applications; and, our ability to obtain and maintain intellectual
property protection for our product candidates. Except as
otherwise required by applicable law and stock exchange rules,
XORTX undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties
affecting XORTX is contained under the heading “Risk Factors” in
XORTX’s Annual Report on Form 20-F filed with the SEC, which is
available on the SEC's website, www.sec.gov (including any
documents forming a part thereof or incorporated by reference
therein), as well as in our reports, public disclosure documents
and other filings with the securities commissions and other
regulatory bodies in Canada, which are available on
www.sedarplus.ca.
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Xortx Therapeutics (TSXV:XRTX)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024